MedPath

Multiple Dose Effect of Oxytocin on Males With High or Low Trait Anxiety

Early Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo nasal spray
Registration Number
NCT03085654
Lead Sponsor
University of Electronic Science and Technology of China
Brief Summary

To examine whether multiple doses of oxytocin have different effects on behavior and neural indices in males with high or low trait anxiety.

Detailed Description

In the present study, healthy male subjects' trait anxiety levels will be assessed by the sub-trait inventory of the State-Trait Anxiety Inventory (STAI). According to subjects' trait anxiety scores, they will be divided into high or low anxiety experimental groups.

Next, experiments will investigate the acute effect (single dose) and chronic effect (3 doses or 5 doses) of oxytocin on brain functional connectivity during resting-state and brain activation in response to watching emotional stimuli using functional magnetic resonance imaging (fMRI). Also the brain structure data (T1 and diffusion tensor imaging, DTI) of subjects will be collected. After finishing the scanning tasks, subjects will be required to rate the emotional valence, intensity and arousal of the pictures shown in the scanner.

During the course of the study subjects will complete a number of questionnaires: Empathy Quotient (EQ), Cheek and Buss Shyness scale (CBSS),Interpersonal Reactivity Index (IRI),Childhood Trauma Questionnaire (CTQ),Beck depression inventory (BDI), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), Liebowitz Social Anxiety Scale (LSAS),Positive and Negative Affect Schedule (PANAS),d2 attention test, and the Visual Analogue Scale for anxiety.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
147
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Low anxiety group (single dose)Oxytocin nasal sprayOxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.
Low anxiety group (3 doses)Oxytocin nasal sprayOxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.
Low anxiety group (5 doses)Oxytocin nasal sprayOxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.
High anxiety group (3 doses)Placebo nasal sprayOxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.
High anxiety group (3 doses)Oxytocin nasal sprayOxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.
High anxiety group (5 doses)Placebo nasal sprayOxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.
Low anxiety group (single dose)Placebo nasal sprayOxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.
High anxiety group (single dose)Oxytocin nasal sprayOxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.
Low anxiety group (5 doses)Placebo nasal sprayOxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.
High anxiety group (single dose)Placebo nasal sprayOxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.
High anxiety group (5 doses)Oxytocin nasal sprayOxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.
Low anxiety group (3 doses)Placebo nasal sprayOxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.
Primary Outcome Measures
NameTimeMethod
Changes between acute and chronic administration of oxytocin on amygdala connectivity as assessed by fMRI5 days

Changes in neural connectivity between first dose and repeated dose will be assessed over the time course of 5 days

Changes between acute and chronic administration of oxytocin on amygdala activity as assessed by fMRI5 days

Changes in neural activity between first dose and repeated dose will be assessed over the time course of 5 days

Secondary Outcome Measures
NameTimeMethod
Interaction of acute and chronic treatment effects with trait anxiety on neural activity5 days

The high and low trait anxiety groups will be compared with respect to differences in the acute effects (single dose, day 1) and changes of effects with chronic treatment over the course of 5 days.

Interaction of acute and chronic treatment effects with trait anxiety on neural connectivity5 days

The high and low trait anxiety groups will be compared with respect to differences in the acute effects (single dose, day 1) and changes of effects with chronic treatment over the course of 5 days.

Interaction of treatment effects on arousal ratings with trait anxiety (acute and changes with chronic treatment)5 days

The high and low trait anxiety groups will be compared with respect to differences in the acute (single dose, day 1) treatment effects and changes with chronic treatment (5 days)

Effects of oxytocin on arousal ratings of emotional stimuli (acute and changes with chronic treatment)5 days

Subjects will rate arousal of emotional stimuli using Likert Scales

Effects of oxytocin on valence ratings of emotional stimuli (acute and changes with chronic treatment)5 days

Subjects will rate valence of emotional stimuli using Likert Scales

Interaction of treatment effects on valence ratings with trait anxiety (acute and changes with chronic treatment)5 days

The high and low trait anxiety groups will be compared with respect to differences in the acute (single dose, day 1) treatment effects and changes with chronic treatment (5 days)

Trial Locations

Locations (1)

school of life science and technology, University of Electronic Science and Technology of China

🇨🇳

Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath